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The definition of diabetes control varies widely
among specialists of the disease. Proponents of
"good" control believe that the goals of appropriate
therapy for diabetes should include an all-out effort
to obtain levels of fasting and postprandial blood
glucose as close to those in the non-diabetic as possible. Certainly, good control has been proven to
accomplish the following :
1. Prevention of ketoacidosis
2. Prevention of severe hypoglycemia
3. Decrease in perinatal mortality and morbidity
4. Promotion of normal growth and development of the juvenile diabetic
5. Prevention of, or inhibition of, infection
The evidence that hyperglycemia is responsible
for vascular complications, particularly microvascular disease, and that good control will prevent
or inhibit the rapidity of the development of this
pathologic process, or even reverse it, is the basis of
this presentation.
·
At the outset, however, it must be appreciated
that retinopathy, nephropathy, neuropathy, and
large vessel disease may be the presenting manifestations of diabetes, and that it is possible to have extensive vascular complications in the presence of relatively mild glucose intolerance. Furthermore, 20% of
juvenile-onset type, ketosis-prone diabetics of more
than 25-years duration with continuous hyperglycemia do not have clinically impressive retinopathy
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or nephropathy. Also, it has been noted that large
vessel disease or neuropathy is absent in 20% to 40%
of insulin-dependent diabetics.
The evidence for good control is largely based on
the following observations:
I.
2.
3.
4.
5.

Clinical studies
Animal studies
Histologic and electron microscopic data
Biochemical studies
Altered coagulopathy, viscosity, and hypoxia

Recent studies in well-controlled juvenile diabetics indicate that serial biopsies of quadriceps muscle
have demonstrated ''.thinning" of previously thickened capillary basement membrane, in contrast to
persistent and increasing thickening of capillary basement membrane in poorly controlled diabetic patients. In addition , it has recently been demonstrated
that diabetic vascular lesions developed in normal
kidneys transplanted into patients with diabetes mellitus after a period of two years, while transplanted
kidneys in non-diabetic control patients of the same
age and type remained unaffected; this also gives
great support to the concept of good control.
Animal studies with diabetic Chinese hamsters,
mice, rats, dogs, and monkeys have indicated that
good control with insulin therapy or islet transplantation prevents or reverses lesions in the eyes,
kidneys, or nerves.
Histologic and electron microscopic studies of
capillary basement membrane of muscle have given
conflicting results. One group of observers indicates
that basement thickening is already genetically predetermined, while other investigators relate capillary
basement membrane thickening to the duration of
diabetes. Methodology of technique, the patient' s
age, unknown duration of existing diabetes, and cri17

,18
teria for the diagnosis of diabetes have to be clarified
before coming to definitive conclusions.
Biochemical studies indicate that hyperglycemia
or insulin deficiency produces alteration in vascular
basement membrane composition, as well as accumulation of glucose-derived substances, such as sorbitol
in the lens of the eye, Schwann' s cell, and aorta.
Recently, an elevation of glycolysated hemoglobin
(HbAJc) has been noted in the blood of diabetic mice
as well as human diabetics. The glycolysation of hemoglobin appears to be a post-synthetic modification
of HbA which is dependent on the degree and duration of hyperglycemia.
Recent data reveal that platelet aggregation is
more intense in diabetic patients, with increased sensitivity of platelets to aggregation from adenosine
diphosphate (ADP) and epinephrine. This sensitivity
correlates with elevated levels of Von Willebrand factor, which in turn appears to be influenced by growth
hormone. Also, platelets from diabetic subjects are
more sensitive to arachidonic acid-induced aggregation, which can be abolished by aspirin, which is a
prostoglandin synthetase-inhibitor.
Spontaneous fibrinolytic activity of the blood is
abnormally low in persons with diabetes mellitus,
and implies a poor defense mechanism against fibrin
deposits in the vessel walls, which conceivably may
contribute to the development of diabetic micro-
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angiopathy. Increased red blood cell aggregation and
alterations in plasma protein changes in diabetics,
with their effects on blood viscosity and flow , may
also play a role in accelerating the rate of progression
of diabetic microangiopathy .
In addition, the decreased reactivity of HbAlc
with 2,3 diphosphoglycerate might impair oxygen unloading in diabetes, and contribute to tissue hypoxia,
which may have pathogenetic implications in the development of diabetic angiopathy.
Whether reversal of hyperglycemia, as well as
the use of agents to inhibit some of the above-described adverse effects of the diabetic milieu, may
affect the development of diabetic microangiopathy is
far from settled. Consideration must be given to more
intense regulation of dietary factors; use of the newer
oral hypoglycemic agents; administration of insulin
three or four times daily for better control; long-term
studies on the use of aspirin, and other platelet-aggregating inhibitors, as well as phosphate supplements;
availability and effectiveness of growth hormone inhibiting agents; the use of substances which can interfere with the post-ribosomal steps of basement membrane assembly; and finally , improvements in the
delivery of insulin, whether it be by better biomechanical engineering or by increased knowledge of
immunologic and other biologic defenses in the use of
islet or organ transplantation.

